A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase III clinical studies demonstrating which therapeutic approach, if any, would prolong life with no significant morbidity. Radiotherapy has been the main therapeutic modality with a curative potential for patients with post-RP PSA relapse. This review article depicts issues and challenges in the management of patients with post-RP PSA relapse, presents the literature data for the efficacy of salvage radiotherapy, either alone or in combination of androgen ablation therapy, and discusses future directions that can optimize treatment strategies.

Citations

Citations to this article as recorded by  

• Long-term clinical outcomes after salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy
  Kenta Onishi, Yasushi Nakai, Fumisato Maesaka, Mitsuru Tomizawa, Takuto Shimizu, Shunta Hori, Daisuke Gotoh, Makito Miyake, Kazumasa Torimoto, Kaori Yamaki, Isao Asakawa, Fumiaki Isohashi, Kiyohide Fujimoto, Nobumichi Tanaka
  Japanese Journal of Clinical Oncology.2025;[Epub]     CrossRef
• Salvage Radiotherapy Following Nonradiotherapy Ablative Techniques for Primary Prostate Cancer: A Systematic Review and Meta-analysis
  Osama Mohamad, Lucas Mose, Maiwand Ahmadsei, Ramez Kouzy, Constantinos Zamboglou, Luca Nicosia, Filippo Alongi, Thomas Zilli, Stefano Arcangeli, Giulia Marvaso, Barbara A. Jereczek-Fossa, Matthias Guckenberger, Daniel M. Aebersold, Mohamed Shelan
  European Urology Focus.2025;[Epub]     CrossRef
• Diospyros rhodocalyx Kurz induces mitochondrial-mediated apoptosis via BAX, Bcl-2, and caspase-3 pathways in LNCaP human prostate cancer cell line
  Chayisara Phongsuwichetsak, Thummaruk Suksrichavalit, Chawalit Chatupheeraphat, Warawan Eiamphungporn, Sakda Yainoy, Vichanan Yamkamon
  PeerJ.2024; 12: e17637.     CrossRef
• Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial
  Elton Trigo Teixeira Leite, Clarissa Cerchi Angotti Ramos, Victor Augusto Bertotti Ribeiro, Bernardo Peres Salvajoli, William Carlos Nahas, João Victor Salvajoli, Fabio Ynoe Moraes
  International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1263.     CrossRef
• Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
  Olayinka A. Abiodun-Ojo, Ashesh B. Jani, Akinyemi A. Akintayo, Oladunni O. Akin-Akintayo, Oluwaseun A. Odewole, Funmilayo I. Tade, Shreyas S. Joshi, Viraj A. Master, Bridget Fielder, Raghuveer K. Halkar, Chao Zhang, Subir Goyal, Mark M. Goodman, David M.
  Journal of Nuclear Medicine.2021; 62(8): 1089.     CrossRef
• Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
  Changhoon Song, Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Seok-Soo Byun, Choung-Soo Kim, Sang Eun Lee, Jae-Sung Kim, Christopher J.D. Wallis
  PLOS ONE.2019; 14(4): e0215057.     CrossRef
• Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
  Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Jean-Léon Lagrange, Stéphane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M Dubray, Stéphanie Servagi-Vernat, Jean-Philippe Suchaud, Gilles Crehan
  The Lancet Oncology.2019; 20(12): 1740.     CrossRef
• Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy
  Esther Mena, Maria L. Lindenberg, Joanna H. Shih, Stephen Adler, Stephanie Harmon, Ethan Bergvall, Deborah Citrin, William Dahut, Anita T. Ton, Yolanda McKinney, Juanita Weaver, Philip Eclarinal, Alicia Forest, George Afari, Sibaprasad Bhattacharyya, Ronn
  European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(1): 4.     CrossRef
• Recent advances in radiation oncology: multimodal targeting of high risk and recurrent prostate cancer
  Young Kwok, Adeel Kaiser, Stephanie R. Rice, Randi Cohen, Mark Mishra
  Current Opinion in Oncology.2018; 30(3): 165.     CrossRef
• Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer
  Oladunni O. Akin-Akintayo, Ashesh B. Jani, Oluwaseun Odewole, Funmilayo I. Tade, Peter T. Nieh, Viraj A. Master, Leah M. Bellamy, Raghuveer K. Halkar, Chao Zhang, Zhengjia Chen, Mark M. Goodman, David M. Schuster
  Clinical Nuclear Medicine.2017; 42(1): e22.     CrossRef
• The Trend of Uro-Oncologist About Blood Test and Imaging Studies for the Diagnosis of Biochemical Recurrence in Korea
  Sung Pil Seo, Won Tae Kim, Ho Won Kang, Yong-June Kim, Sang-Cheol Lee, Wun-Jae Kim, So Young Kim, Jong-Hyock Park, Seok Joong Yun
  The Korean Journal of Urological Oncology.2017; 15(3): 131.     CrossRef
• Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy
  Wan Song, Hwang Gyun Jeon, Hyun Hwan Sung, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee
  International Journal of Urology.2016; 23(1): 56.     CrossRef
• Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
  Christian Carrie, Ali Hasbini, Guy de Laroche, Pierre Richaud, Stéphane Guerif, Igor Latorzeff, Stéphane Supiot, Mathieu Bosset, Jean-Léon Lagrange, Véronique Beckendorf, François Lesaunier, Bernard Dubray, Jean-Philippe Wagner, Tan Dat N'Guyen, Jean-Phil
  The Lancet Oncology.2016; 17(6): 747.     CrossRef
• Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial
  Eduard Schreibmann, David M. Schuster, Peter J. Rossi, Joseph Shelton, Sherrie Cooper, Ashesh B. Jani
  International Journal of Radiation Oncology*Biology*Physics.2016; 96(1): 206.     CrossRef
• Detection of a second malignancy in prostate cancer patients by using [18F]Choline PET/CT: a case series
  Martina Sollini, Francesco Pasqualetti, Marzio Perri, Gabriele Coraggio, Paolo Castellucci, Massimo Roncali, Roberto Boni, Elena Lazzeri, Maria Galeandro, Fabiola Paiar, Annibale Versari, Paola Anna Erba
  Cancer Imaging.2016;[Epub]     CrossRef
• Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
  Xiaofang Wang, Wenjuan Zhang, Zi Yan, Yupei Liang, Lihui Li, Xiaoli Yu, Yan Feng, Shen Fu, Yanmei Zhang, Hu Zhao, Jinha Yu, Lak Shin Jeong, Xiaomao Guo, Lijun Jia
  Oncotarget.2016; 7(25): 38380.     CrossRef
• Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study
  Takashi Mizowaki, Manabu Aoki, Katsumasa Nakamura, Atsunori Yorozu, Masaki Kokubo, Katsuyuki Karasawa, Takuyo Kozuka, Nobuaki Nakajima, Keisuke Sasai, Tetsuo Akimoto
  Journal of Radiation Research.2015; 56(4): 750.     CrossRef
• Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome
  Michael G. Heckman, Katherine S. Tzou, Colleen S. Thomas, Thomas M. Pisansky, Steven E. Schild, William W. Wong, Richard J. Lee, Melanie C. Bois, Waleed Brinjikji, Jennifer L. Peterson, Larry C. Daugherty, Stephen J. Ko, Steven J. Buskirk
  Journal of Radiation Oncology.2014; 3(1): 81.     CrossRef
• Anti-3-[ 18 F]FACBC Positron Emission Tomography-Computerized Tomography and 111 In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prosta
  David M. Schuster, Peter T. Nieh, Ashesh B. Jani, Rianot Amzat, F. DuBois Bowman, Raghuveer K. Halkar, Viraj A. Master, Jonathon A. Nye, Oluwaseun A. Odewole, Adeboye O. Osunkoya, Bital Savir-Baruch, Pooneh Alaei-Taleghani, Mark M. Goodman
  Journal of Urology.2014; 191(5): 1446.     CrossRef
• Salvage Low-Dose-Rate Brachytherapy for Prostate Cancer Local Recurrence after Radical Prostatectomy: Our First three Patients
  Emilio Gastaldi, Fabrizio Gallo, Luciano Chiono, Claudio Giberti
  Urologia Journal.2014; 81(1): 46.     CrossRef
• Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer
  Michael G. Heckman, Katherine S. Tzou, Alexander S. Parker, Thomas M. Pisansky, Steven E. Schild, Tracy W. Hilton, Vivek N. Patel, Liset Pelaez, Li Yan Khor, Jennifer L. Peterson, Larry C. Daugherty, Laura A. Vallow, Alan Pollack, Steven J. Buskirk
  Journal of Radiation Oncology.2013; 2(3): 309.     CrossRef
• Treatment of men with rising prostate-specific antigen levels following radical prostatectomy
  Katherine Tzou, Winston W Tan, Steven Buskirk
  Expert Review of Anticancer Therapy.2011; 11(1): 125.     CrossRef
• Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT
  David M. Schuster, Bital Savir-Baruch, Peter T. Nieh, Viraj A. Master, Raghuveer K. Halkar, Peter J. Rossi, Melinda M. Lewis, Jonathon A. Nye, Weiping Yu, F. DuBois Bowman, Mark M. Goodman
  Radiology.2011; 259(3): 852.     CrossRef
• EUS-guided fiducial placement after radical prostatectomy before targeted radiation therapy for prostate cancer recurrence
  Julie Yang, May Abdel-Wahab, Afonso Ribeiro
  Gastrointestinal Endoscopy.2011; 73(6): 1302.     CrossRef

Citations

Citations to this article as recorded by  

• Modulation of inflammatory mediators underlies the antitumor effect of the combination of morusin and docetaxel on prostate cancer cells
  Sana A. Fadil, Dina A.I. Albadawi, Khalid Z. Alshali, Hossam M. Abdallah, Mona M. Saber
  Biomedicine & Pharmacotherapy.2024; 180: 117572.     CrossRef
• Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
  Kwonoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Hyo Jin Lee, Jae Lyun Lee
  Yonsei Medical Journal.2023; 64(2): 86.     CrossRef
• Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer
  Bumjin Lim, Wonchul Lee, Yoon Soo Kyung, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
  Journal of Cancer Research and Clinical Oncology.2022; 148(3): 727.     CrossRef
• AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE
  Devashish Kaushal, Rajeev Sood
  INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 78.     CrossRef
• A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
  Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee, Se Hoon Park
  BMC Cancer.2021;[Epub]     CrossRef
• Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
  Myung-Won Lee, Hyewon Ryu, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Young Bok Ko, Hyo-Jin Lee
  Medicine.2020; 99(17): e19931.     CrossRef
• A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
  Sang Eun Yoon, Youjin Kim, Jangho Cho, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byoung Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Su Jin Lee, Se Hoon Park
  BMC Urology.2019;[Epub]     CrossRef
• Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells
  Chongyi Yang, Weijie Zhang, Jie Wang, Pengpeng Chen, Jiangjiang Jin
  Molecular Medicine Reports.2019;[Epub]     CrossRef
• Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
  Hiromi Sato, Shintaro Narita, Norihiko Tsuchiya, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Kyoko Nomura, Tomonori Habuchi
  BMC Urology.2018;[Epub]     CrossRef
• A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
  Hae Su Kim, Ji Yun Lee, Su Jin Lee, Ho Yeong Lim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Se Hoon Park
  BMC Urology.2017;[Epub]     CrossRef
• Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
  Dong Hoon Lee, Jung Ho Kim, Won Ik Seo, Jong Kil Nam, Tae Nam Kim, Cheol Kyu Oh, Soo Dong Kim, Sung-Woo Park, Jae Sung Chung, Sang Hyun Park, Wan Lee, Gyung Tak Sung, Moon Kee Chung, Jae Il Chung
  The Korean Journal of Urological Oncology.2017; 15(2): 59.     CrossRef
• Hormonal therapy and chemotherapy for advanced prostate cancer
  Jae Lyun Lee
  Journal of the Korean Medical Association.2015; 58(1): 30.     CrossRef
• Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
  J-L Lee, J-H Ahn, M K Choi, Y Kim, S-W Hong, K-H Lee, I-G Jeong, C Song, B-S Hong, J H Hong, H Ahn
  British Journal of Cancer.2014; 110(10): 2472.     CrossRef
• Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
  Jae-Lyun Lee, Se Hoon Park, Su-Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim
  Cancer Chemotherapy and Pharmacology.2014; 74(5): 1005.     CrossRef
• Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer
  Whi-An Kwon, Tae Hoon Oh, Jae Whan Lee, Seung Chol Park
  Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3443.     CrossRef
• Clinical predictor of survival following docetaxel-based chemotherapy
  HSIANG-YING LEE, WEN-JENG WU, CHUN-HSIUNG HUANG, YII-HER CHOU, CHUN-NUNG HUANG, YUNG-CHIN LEE, KAI-FU YANG, MEI-HUI LEE, SHU-PIN HUANG
  Oncology Letters.2014; 8(4): 1788.     CrossRef
• Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
  Geehyun Song, Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
  Prostate International.2013; 1(3): 125.     CrossRef
• Quimioterapia sistémica basada en docetaxel en hombres coreanos mayores con cáncer de próstata resistente a la castración
  S.C.H. Park, L.J. Whan, R.J. Sik
  Actas Urológicas Españolas.2012; 36(7): 425.     CrossRef
• Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer
  S.C.H. Park, L.J. Whan, R.J. Sik
  Actas Urológicas Españolas (English Edition).2012; 36(7): 425.     CrossRef

Citations

Citations to this article as recorded by  

• Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer
  Heonwoo Lee, Min-Hee Ryu, In-Seob Lee, Ji Yong Ahn, Jeong Hoon Lee, Hyungeun Lee, Hyung-Don Kim, Young Soo Park
  Gastric Cancer.2025;[Epub]     CrossRef
• Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer
  Fei-Yu Wang, Xiang-Ming Huang, Yu-Qing Cao, Jie Cao, Jie Ni, Ke Li, Min Lu, Xin-En Huang
  Journal of Gastrointestinal Cancer.2024; 55(3): 1105.     CrossRef
• Prognostic significance of interim 18F‐fluorodeoxyglucose positron emission tomography–computed tomography volumetric parameters in metastatic or recurrent gastric cancer
  Suk‐young Lee, Hyo Jung Seo, Sungeun Kim, Jae Seon Eo, Sang Cheul Oh
  Asia-Pacific Journal of Clinical Oncology.2018;[Epub]     CrossRef
• Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
  Yan-qin Lan, Ling-jun Kong, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang, Dong-ta Zhong
  Cancer Chemotherapy and Pharmacology.2018; 81(6): 1007.     CrossRef
• Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer
  Yan-qin Lan, Ri-ping Wu, Xiao-bing Huang, Xin-li Wang, Dong-ta Zhong, Chuan-yong Huang, Jin-tian Song
  Tumori Journal.2018; 104(1): 22.     CrossRef
• Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status
  Ilhan Hacibekiroglu, Hilmi Kodaz, Bulent Erdogan, Esma Turkmen, Asim Esenkaya, Sernaz Uzunoglu, Irfan Cicin
  Asian Pacific Journal of Cancer Prevention.2015; 16(6): 2355.     CrossRef
• Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer
  ILHAN HACIBEKIROGLU, HILMI KODAZ, BULENT ERDOGAN, ESMA TURKMEN, ASIM ESENKAYA, YILMAZ ONAL, SERNAZ UZUNOGLU, IRFAN CICIN
  Molecular and Clinical Oncology.2015; 3(5): 1160.     CrossRef
• Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
  Zhan-Dong Zhang, Ye Kong, Wei Yang, Bin Zhang, Yong-Lei Zhang, Er-Min Ma, Hong-Xing Liu, Xiao-Bin Chen, Ya-Wei Hua
  World Journal of Surgical Oncology.2014;[Epub]     CrossRef
• Management of advanced gastric cancer
  Timothy J Price, Jeremy D Shapiro, Eva Segelov, Christos S Karapetis, Nick Pavlakis, Eric Van Cutsem, Manish A Shah, Yoon-Koo Kang, Niall C Tebbutt
  Expert Review of Gastroenterology & Hepatology.2012; 6(2): 199.     CrossRef
• Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
  Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
  Cancer Research and Treatment.2012; 44(4): 235.     CrossRef
• Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
  K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
  Japanese Journal of Clinical Oncology.2012; 42(8): 686.     CrossRef
• A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin
  Isao Ito, Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Kaoru Yasuda, Takenori Ozaki, Tomoki Kosugi, Yoshinari Yasuda, Waichi Sato, Naotake Tsuboi, Shoichi Maruyama, Enyu Imai, Seiichi Matsuo
  Clinical and Experimental Nephrology.2012; 16(3): 490.     CrossRef
• Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status
  HYEONG SU KIM, JUNG HAN KIM, HEE JUN KIM, HYUN JOO JANG, JIN BAE KIM, JI WON KIM, SO YOUNG JUNG, BYUNG CHUN KIM, DAE HYUN YANG, SOAH PARK, KEONG JU KIM, SOON IL LEE, DAE YOUNG ZANG
  Oncology Letters.2012; 3(2): 425.     CrossRef
• Targeted Therapies for Gastric Cancer
  Jaclyn Yoong, Michael Michael, Trevor Leong
  Drugs.2011; 71(11): 1367.     CrossRef

Citations

Citations to this article as recorded by  

• Strategic Developments in Polymer-Functionalized Liposomes for Targeted Colon Cancer Therapy: An Updated Review of Clinical Trial Data and Future Horizons
  Satyam Sharma, Moitrai Chakraborty, Dharmendra Yadav, Aniket Dhullap, Raghuraj Singh, Rahul Kumar Verma, Sankha Bhattacharya, Sanjiv Singh
  Biomacromolecules.2024; 25(9): 5650.     CrossRef
• Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma
  Domenico D’Arca, Leda Severi, Stefania Ferrari, Luca Dozza, Gaetano Marverti, Fulvio Magni, Clizia Chinello, Lisa Pagani, Lorenzo Tagliazucchi, Marco Villani, Gianluca d’Addese, Isabella Piga, Vincenza Conteduca, Lorena Rossi, Giorgia Gurioli, Ugo De Gior
  Cancers.2023; 15(2): 412.     CrossRef
• Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1–7]
  Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
  Biochimie.2022; 200: 1.     CrossRef
• Melatonin as an adjuvant treatment modality with doxorubicin
  Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
  Biochimie.2022; 202: 49.     CrossRef
• A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)
  Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
  Future Science OA.2021;[Epub]     CrossRef
• Design principles of drug combinations for chemotherapy
  Debra Wu, Anusha Pusuluri, Douglas Vogus, Vinu Krishnan, C. Wyatt Shields, Jayoung Kim, Amaya Razmi, Samir Mitragotri
  Journal of Controlled Release.2020; 323: 36.     CrossRef
• A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies
  Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Chihiro Kondoh, Isao Oze, Kyoko Kato, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
  Advances in Therapy.2020; 37(6): 2853.     CrossRef
• The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
  Masoud Najafi, Keywan Mortezaee, Mahban Rahimifard, Bagher Farhood, Hamed Haghi-Aminjan
  Life Sciences.2020; 257: 118051.     CrossRef
• Potential therapeutic effects of curcumin in gastric cancer
  Nastaran Barati, Amir A. Momtazi‐Borojeni, Muhammed Majeed, Amirhossein Sahebkar
  Journal of Cellular Physiology.2019; 234(3): 2317.     CrossRef
• Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
  Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
  Cancer Research and Treatment.2019; 51(1): 223.     CrossRef
• Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
  Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
  Gastric Cancer.2018; 21(6): 1050.     CrossRef
• Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
  In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
  PLOS ONE.2018; 13(6): e0198544.     CrossRef
• A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
  In Sil Choi, Jee Hyun Kim, Ju Hyun Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
  PLOS ONE.2018; 13(10): e0205853.     CrossRef
• Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
  Vincenza Conteduca, Giorgia Gurioli, Lorena Rossi, Emanuela Scarpi, Cristian Lolli, Giuseppe Schepisi, Alberto Farolfi, Delia De Lisi, Valentina Gallà, Salvatore Luca Burgio, Cecilia Menna, Andrea Amadori, Lorena Losi, Dino Amadori, Maria Paola Costi, Ugo
  BMC Cancer.2018;[Epub]     CrossRef
• Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
  Sung Yong Oh, Aesun Shin, Seong-Geun Kim, Jung-Ah Hwang, Seung Hyun Hong, Yeon-Su Lee, Hyuk-Chan Kwon
  Oncotarget.2016; 7(21): 31204.     CrossRef
• Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
  Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
  Tumor Biology.2014; 35(4): 2941.     CrossRef
• Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
  Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim, Hyo-Jin Kim
  BMC Cancer.2013;[Epub]     CrossRef
• The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
  Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Jung-Ah Hwang, Seung Hyun Hong, Christian A Graves, Kevin Camphausen, Hyo-Jin Kim, Yeon-Su Lee
  BMC Cancer.2013;[Epub]     CrossRef
• Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy
  Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Christian A. Graves, Kevin Camphausen, Hyo-Jin Kim
  Chemotherapy.2012; 58(6): 426.     CrossRef
• Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
  K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
  Japanese Journal of Clinical Oncology.2012; 42(8): 686.     CrossRef
• The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma
  Yanzhi Bi, Dongxiang Zeng, Yang Ling
  The Chinese-German Journal of Clinical Oncology.2012; 11(6): 336.     CrossRef
• Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor
  Jun Chul Park, Jae-Hoon Lee, Kungseok Cheoi, Hyunsoo Chung, Mi Jin Yun, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee
  European Journal of Nuclear Medicine and Molecular Imaging.2012; 39(7): 1107.     CrossRef
• Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy
  Yun Jeung Kim, Pyung Gohn Goh, Eui Sik Kim, Su Youn Lee, Hee Seok Moon, Eaum Seok Lee, Jae Kyu Sung, Seok Hyun Kim, Byung Seok Lee, Hyun Yong Jeong
  The Korean Journal of Gastroenterology.2011; 58(6): 311.     CrossRef
• Targeted Therapies for Gastric Cancer
  Jaclyn Yoong, Michael Michael, Trevor Leong
  Drugs.2011; 71(11): 1367.     CrossRef
• Evolving Standards of Care in Advanced Gastric Cancer
  Jean-Emmanuel Kurtz, Patrick Dufour
  Future Oncology.2011; 7(12): 1441.     CrossRef

Citations

Citations to this article as recorded by  

• Preoperative lymph node metastasis risk assessment in invasive micropapillary carcinoma of the breast: development of a machine learning-based predictive model with a web-based calculator
  Yan Zhang, Nan Wang, Yuxin Qiu, Yingxiao Jiang, Peiyan Qin, Xiaoxiao Wang, Yang Li, Xiangdi Meng, Furong Hao
  World Journal of Surgical Oncology.2025;[Epub]     CrossRef
• Is Programmed Death-Ligand 1 of Prognostic Significance in Triple-Negative Female Mammary Carcinoma?
  Amal Mostafa Sanad, Wael Shawky Ibrahim, Iman Mohamed Ezzo, Rania Mohamed Sabry
  Journal of Microscopy and Ultrastructure.2024; 12(1): 6.     CrossRef
• AXILLARY LYMPH NODE METASTASIS IN SONOLOGICALLY NODE-NEGATIVE BREAST CARCINOMA
  ADARSA S BABU, SUNIL S, JOMINE JOSE
  Asian Journal of Pharmaceutical and Clinical Research.2024; : 26.     CrossRef
• Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years?
  Katherine Grant, Xiang Yuen Po, Leong Tiong
  ANZ Journal of Surgery.2024; 94(12): 2159.     CrossRef
• Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival
  Billy Shui‐Wun Lai, Julia Y Tsang, Joshua J Li, Ivan K Poon, Gary M Tse
  Histopathology.2023; 82(6): 899.     CrossRef
• CORRELATION OF RECEPTOR STATUS WITH AXILLARY NODAL METASTASIS AND OTHER PROGNOSTIC FACTORS IN CARCINOMA BREAST : INDIAN PERSPECTIVE
  Mohammad Raja, Shailendra Rai, Aklesh Kumar Maurya, Basanti Mazumdar
  INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2022; : 30.     CrossRef
• Isocorrole-Loaded Polymer Nanoparticles for Photothermal Therapy under 980 nm Light Excitation
  Maximilian R. J. Marek, Trong-Nhan Pham, Jianxin Wang, Qiuqi Cai, Glenn P. A. Yap, Emily S. Day, Joel Rosenthal
  ACS Omega.2022; 7(41): 36653.     CrossRef
• Differences in the Immune Response of the Nonmetastatic Axillary Lymph Nodes between Triple-Negative and Luminal A Breast Cancer Surrogate Subtypes
  Carlos López, Albert Gibert-Ramos, Ramón Bosch, Anna Korzynska, Marcial García-Rojo, Gloria Bueno, Joan Francesc García-Fontgivell, Salomé Martínez González, Laia Fontoura, Andrea Gras Navarro, Esther Sauras Colón, Júlia Casanova Ribes, Lukasz Roszkowiak,
  The American Journal of Pathology.2021; 191(3): 545.     CrossRef
• Axillary management based on American college of surgeons oncology group Z0011 criteria makes it possible to omit intraoperative diagnosis of sentinel lymph nodes in early breast cancer patients
  Nobuyoshi Kittaka, Satomi Nakajima, Takaaki Hatano, Yukiko Seto, Hiroki Kusama, Saki Matsui, Minako Nishio, Fumie Fujisawa, Keiichiro Honma, Takahiro Nakayama, Yasuhiro Tamaki
  The Breast Journal.2021; 27(11): 804.     CrossRef
• Development of a Novel Tool for the Retrieval and Analysis of Hormone Receptor Expression Characteristics in Metastatic Breast Cancer via Data Mining on Pathology Reports
  Kai-Po Chang, John Wang, Chi-Chang Chang, Yen-Wei Chu, Yungang Xu
  BioMed Research International.2020;[Epub]     CrossRef
• Accuracy of CEUS-guided sentinel lymph node biopsy in early-stage breast cancer: a study review and meta-analysis
  Qiuxia Cui, Li Dai, Jialu Li, Jialei Xue
  World Journal of Surgical Oncology.2020;[Epub]     CrossRef
• Preoperative Axillary Ultrasound Helps in the Identification of a Limited Nodal Burden in Breast Cancer Patients
  Haiyu Luo, Yongqian Mo, Jieyu Zhong, Yushen Zhang, Lizhang Zhu, Xiaoxin Shi, Yun Chen
  Ultrasound Quarterly.2020; 36(2): 173.     CrossRef
• Lymph node positivity in different early breast carcinoma phenotypes: a predictive model
  Gilles Houvenaeghel, Eric Lambaudie, Jean-Marc Classe, Chafika Mazouni, Sylvia Giard, Monique Cohen, Christelle Faure, Hélène Charitansky, Roman Rouzier, Emile Daraï, Delphine Hudry, Pierre Azuar, Richard Villet, Pierre Gimbergues, Christine Tunon de Lara
  BMC Cancer.2019;[Epub]     CrossRef
• Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis
  Eun-Kyu Kim, Ae Kyung Park, Eunyoung Ko, Woong-Yang Park, Kyung-Min Lee, Dong-Young Noh, Wonshik Han
  Breast Cancer Research and Treatment.2019; 178(1): 185.     CrossRef
• Preoperative Axillary Ultrasound in the Selection of Patients With a Heavy Axillary Tumor Burden in Early‐Stage Breast Cancer: What Leads to False‐Positive Results?
  Ying Zhu, Wei Zhou, Xiao‐hong Jia, Ou Huang, Wei‐wei Zhan
  Journal of Ultrasound in Medicine.2018; 37(6): 1357.     CrossRef
• Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer
  Jiwoong Jung, Young Jin Suh, Byung Kyun Ko, Eun Sook Lee, Eun‐Kyu Kim, Nam Sun Paik, Kyung Do Byun, Ki‐Tae Hwang
  Cancer Medicine.2018; 7(11): 5514.     CrossRef
• A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran
  Roham Salek, Fatemeh Varshoee Tabrizi, Kamran Ghaffarzadegan, Golnaz Sabouri, Azar Fanipakdel
  Iranian Journal of Cancer Prevention.2017;[Epub]     CrossRef
• Risk Stratification For Axillary Lymph Node Metastases in Breast Cancer Patients
  Seong Jong Yun, Yu-Mee Sohn, Mirinae Seo
  Ultrasound Quarterly.2017; 33(1): 15.     CrossRef
• Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis
  Young-Sil An, Doo Kyoung Kang, Yongsik Jung, Tae Hee Kim
  Medicine.2017; 96(45): e8557.     CrossRef
• The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer
  Keun-Yong Eom, Min Hye Jang, So Yeon Park, Eun Young Kang, Sung Won Kim, Jee Hyun Kim, Jae-Sung Kim, In Ah Kim
  Cancer Research and Treatment.2016; 48(1): 125.     CrossRef
• Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer
  Katsutoshi Enokido, Chie Watanabe, Seigo Nakamura, Akiko Ogiya, Tomo Osako, Futoshi Akiyama, Akiyo Yoshimura, Hiroji Iwata, Shinji Ohno, Yasuyuki Kojima, Koichiro Tsugawa, Kazuyoshi Motomura, Naoki Hayashi, Hideko Yamauchi, Nobuaki Sato
  Clinical Breast Cancer.2016; 16(4): 299.     CrossRef
• Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer
  Mi Joo Chung, Jong Hoon Lee, Sung Hwan Kim, Young Jin Suh, Hyun Joo Choi
  Medicine.2016; 95(20): e3689.     CrossRef
• Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer
  Riccardo Ponzone, Fiorella Ruatta, Marco Gatti, Isabella Castellano, Elena Geuna, Giulia Amato, Franziska Kubatzki, Paola Sgandurra, Anna Sapino, Filippo Montemurro
  Cancer Treatment Reviews.2016; 48: 1.     CrossRef
• HER2 expression is a strong independent predictor of nodal metastasis in breast cancer
  Ahmed R.H. Ahmed
  Journal of the Egyptian National Cancer Institute.2016; 28(4): 219.     CrossRef
• Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression
  Manjulata Singh, Shilpaa Mukundan, Maria Jaramillo, Steffi Oesterreich, Shilpa Sant
  Cancer Research.2016; 76(13): 3732.     CrossRef
• Reduced risk of axillary lymphatic spread in triple-negative breast cancer
  Emil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, Niels Kroman, Tove Filtenborg Tvedskov
  Breast Cancer Research and Treatment.2015; 149(1): 229.     CrossRef
• Evaluation of the Flash effect in breast irradiation using TomoDirect: an investigational study
  Dae Gyu Kang, Sung Ill Park, Sung Hwan Kim, Mi Joo Chung, Kwang-Man Lee, Jong Hoon Lee
  Journal of Radiation Research.2015; 56(2): 397.     CrossRef
• Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma
  Z. Chu, H. Lin, X. Liang, R. Huang, J. Tang, Y. Bao, J. Jiang, Q. Zhan, X. Zhou
  Japanese Journal of Clinical Oncology.2015; 45(7): 637.     CrossRef
• Correlation of Various Biomarkers with Axillary Nodal Metastases: Can a Panel of Such Biomarkers Guide Selective Use of Axillary Surgery in T1 Breast Cancer?
  Tufale A. Dass, Sharma Rakesh, K. Patil Prakash, Chandraveer Singh
  Indian Journal of Surgical Oncology.2015; 6(4): 346.     CrossRef
• Setup Error and Effectiveness of Weekly Image-Guided Radiation Therapy of TomoDirect for Early Breast Cancer
  Mi Joo Chung, Guk Jin Lee, Young Jin Suh, Hyo Chun Lee, Sea-Won Lee, Songmi Jeong, Jeong Won Lee, Sung Hwan Kim, Dae Gyu Kang, Jong Hoon Lee
  Cancer Research and Treatment.2015; 47(4): 774.     CrossRef
• Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis
  Zhen-Yu He, San-Gang Wu, Qi Yang, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin
  Medicine.2015; 94(48): e2213.     CrossRef
• Irinotecan and Capecitabine Combination Chemotherapy in a Patient with Triple-negative Breast Cancer Relapsed after Adjuvant Chemotherapy with Anthracycline and Taxane
  Anna Lee, Se-Il Go, Won Sup Lee, Un Seok Lee, Moon Jin Kim, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Jae Min Cho, Jeong-Hee Lee
  Tumori Journal.2015; 101(1): e9.     CrossRef
• A Prediction Model for the Presence of Axillary Lymph Node Involvement in Women with Invasive Breast Cancer: A Focus on Older Women
  Lauren T. Greer, Martin Rosman, W. Charles Mylander, Wen Liang, Robert R. Buras, Anees B. Chagpar, Michael J. Edwards, Lorraine Tafra
  The Breast Journal.2014; 20(2): 147.     CrossRef
• Predictive Role of Tumor Size in Breast Cancer with Axillary Lymph Node Involvement - Can Size of Primary Tumor be used to Omit an Unnecessary Axillary Lymph Node Dissection?
  Elahe Orang, Eisa Tahmasbpour Marzony, Aboulfazl Afsharfard
  Asian Pacific Journal of Cancer Prevention.2013; 14(2): 717.     CrossRef
• Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
  Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
  Cancer Research and Treatment.2013; 45(1): 31.     CrossRef
• The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index
  Yu Koyama, Hiroshi Ichikawa, Jun Sakata, Eiko Sakata, Kumiko Tatsuda, Miki Hasegawa, Chie Toshikawa, Naoko Manba, Mayuko Ikarashi, Toshifumi Wakai
  Advances in Breast Cancer Research.2013; 02(03): 60.     CrossRef
• Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers
  Huiming Zhang, Zhongtao Zhang, Lixue Xuan, Shan Zheng, Lei Guo, Qimin Zhan, Xiang Qu, Baoning Zhang, Yu Wang, Xiang Wang, Yongmei Song
  Clinical and Translational Oncology.2012; 14(3): 225.     CrossRef
• Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma
  C. Ngô, D. Mouttet, Y. De Rycke, F. Reyal, V. Fourchotte, F. Hugonnet, M.C. Falcou, F.C. Bidard, A. Vincent-Salomon, A. Fourquet, S. Alran
  European Journal of Surgical Oncology (EJSO).2012; 38(12): 1211.     CrossRef
• The Incidence and Predictor of Lymph Node Metastasis for Patients with T1mi Breast Cancer Who Underwent Axillary Dissection and Breast Irradiation: An Institutional Analysis
  J. H. Lee, Y. J. Suh, B. Y. Shim, S. H. Kim
  Japanese Journal of Clinical Oncology.2011; 41(10): 1162.     CrossRef
• Predictive Factors Affecting Axillary Lymph Node Metastasis in Patients with Invasive Breast Carcinoma of 1 cm or Less
  Sun Hee Kang, Jihyung Cho
  Journal of the Korean Surgical Society.2011; 80(1): 10.     CrossRef
• Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma
  Sibel Yenidunya, Reyhan Bayrak, Hacer Haltas
  Diagnostic Pathology.2011;[Epub]     CrossRef
• Distance of Breast Cancer From the Skin and Nipple Impacts Axillary Nodal Metastases
  Bijan Ansari, Marilyn J. Morton, Darcy L. Adamczyk, Katie N. Jones, Julie K. Brodt, Amy C. Degnim, James W. Jakub, Christine M. Lohse, Judy C. Boughey
  Annals of Surgical Oncology.2011; 18(11): 3174.     CrossRef
• The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma
  Fabien Reyal, Roman Rouzier, Berenice Depont-Hazelzet, Marc A. Bollet, Jean-Yves Pierga, Severine Alran, Remy J. Salmon, Virginie Fourchotte, Anne Vincent-Salomon, Xavier Sastre-Garau, Martine Antoine, Serge Uzan, Brigitte Sigal-Zafrani, Yann De Rycke, Xi
  PLoS ONE.2011; 6(5): e20297.     CrossRef
• A Straightforward but Not Piecewise Relationship between Age and Lymph Node Status in Chinese Breast Cancer Patients
  Ke-Da Yu, Jun-Jie Li, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Zhi-Ming Shao, Joseph Najbauer
  PLoS ONE.2010; 5(6): e11035.     CrossRef

Citations

Citations to this article as recorded by  

• T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia
  Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi
  Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.2024; 5(4): 412.     CrossRef
• Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica
  Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi
  Advances in Laboratory Medicine / Avances en Medicina de Laboratorio.2024; 5(4): 418.     CrossRef
• BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
  T P Hughes, G Saglio, A Quintás-Cardama, M J Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec, A Hochhaus
  Leukemia.2015; 29(9): 1832.     CrossRef

Citations

Citations to this article as recorded by  

• AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis
  Chun Gong, Wei Li, Jing Wu, Yao-Yao Li, Yi Ma, Li-Wen Tang
  Journal of Radiation Research.2023; 64(1): 33.     CrossRef
• Investigation of the Subcellular Localization-Dependent Anti- or Pro-Tumor Functions of Maspin in Human Lung Adenocarcinoma Cell Line
  Takahiro Matsushige, Tomohiko Sakabe, Yoshihisa Umekita
  Yonago Acta Medica.2022; 65(1): 44.     CrossRef
• Proteome and secretome analysis of pancreatic cancer cells
  Xiang Li, Hui Liu, Matthew D. Dun, Sam Faulkner, Xiaoming Liu, Chen Chen Jiang, Hubert Hondermarck
  PROTEOMICS.2022;[Epub]     CrossRef
• AF8c, a Multi-Kinase Inhibitor Induces Apoptosis by Activating DR5/Nrf2 via ROS in Colorectal Cancer Cells
  Soyeon Jeong, Ahmed K. Farag, Hye Kyeong Yun, Yoon A. Jeong, Dae Yeong Kim, Min Jee Jo, Seong Hye Park, Bo Ram Kim, Jung Lim Kim, Bu Gyeom Kim, Dae-Hee Lee, Eun Joo Roh, Sang Cheul Oh
  Cancers.2022; 14(13): 3043.     CrossRef
• Role of cytoplasmic localization of maspin in promoting cell invasion in breast cancer with aggressive phenotype
  Tomohiko Sakabe, Makoto Wakahara, Goshi Shiota, Yoshihisa Umekita
  Scientific Reports.2021;[Epub]     CrossRef
• The potential function of IKKα in gastric precancerous lesion via mediating Maspin
  Ning Wang, Li-Li Chang
  Tissue and Cell.2020; 65: 101349.     CrossRef
• The roles of MASPIN expression and subcellular localization in non-small cell lung cancer
  Xiao-Fei Wang, Bo Liang, Da-Xiong Zeng, Wei Lei, Cheng Chen, Yan-Bin Chen, Jian-An Huang, Ning Gu, Ye-Han Zhu
  Bioscience Reports.2020;[Epub]     CrossRef
• The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
  Klara Fodor, Nikoletta Dobos, Andrew Schally, Zita Steiber, Gabor Olah, Eva Sipos, Lorant Szekvolgyi, Gabor Halmos
  Oncotarget.2020; 11(2): 175.     CrossRef
• Inhibition of miR-21-5p suppresses high glucose-induced proliferation and angiogenesis of human retinal microvascular endothelial cells by the regulation of AKT and ERK pathways via maspin
  Feng Qiu, Huijuan Tong, Yawen Wang, Jun Tao, Hailin Wang, Lei Chen
  Bioscience, Biotechnology, and Biochemistry.2018; 82(8): 1366.     CrossRef
• Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses
  Jer-Hwa Chang, Chao-Wen Cheng, Yi-Chieh Yang, Wan-Shen Chen, Wen-Yueh Hung, Jyh-Ming Chow, Pai-Sheng Chen, Michael Hsiao, Wei-Jiunn Lee, Ming-Hsien Chien
  Journal of Experimental & Clinical Cancer Research.2018;[Epub]     CrossRef
• IKKα inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line
  Martina Leopizzi, Rossana Cocchiola, Edoardo Milanetti, Domenico Raimondo, Laura Politi, Cesare Giordano, Roberto Scandurra, Anna Scotto d'Abusco
  Chemico-Biological Interactions.2017; 262: 19.     CrossRef
• Quercetin suppresses the metastatic ability of lung cancer through inhibiting Snail-dependent Akt activation and Snail-independent ADAM9 expression pathways
  Jer-Hwa Chang, Shu-Leung Lai, Wan-Shen Chen, Wen-Yueh Hung, Jyh-Ming Chow, Michael Hsiao, Wei-Jiunn Lee, Ming-Hsien Chien
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2017; 1864(10): 1746.     CrossRef
• Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression
  Veronica Henderson, Basil Smith, Liza J Burton, Diandra Randle, Marisha Morris, Valerie A Odero-Marah
  Cell Adhesion & Migration.2015; 9(4): 255.     CrossRef
• Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition
  Nayeong Kim, Soyeon Jeong, Kaipeng Jing, Soyeon Shin, Soyeon Kim, Jun-Young Heo, Gi-Ryang Kweon, Seung-Kiel Park, Tong Wu, Jong-Il Park, Kyu Lim
  BioMed Research International.2015; 2015: 1.     CrossRef
• Different maspin functions in the lung adenocarcinoma A549 and SPC-A1 cell lines
  JUN ZHOU, QIN HUALONG, PENG ZHOU, FENG GUO
  International Journal of Molecular Medicine.2015; 36(5): 1440.     CrossRef
• Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells
  Chenyu Mao, Hao Liu, Ping Chen, Jingjia Ye, Lisong Teng, Zhenyu Jia, Jiang Cao
  Oncotarget.2015; 6(8): 5707.     CrossRef
• TUBB3/βIII-Tubulin Acts through the PTEN/AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Non–Small Cell Lung Cancer
  Joshua A. McCarroll, Pei Pei Gan, Rafael B. Erlich, Marjorie Liu, Tanya Dwarte, Sharon S. Sagnella, Mia C. Akerfeldt, Lu Yang, Amelia L. Parker, Melissa H. Chang, Michael S. Shum, Frances L. Byrne, Maria Kavallaris
  Cancer Research.2015; 75(2): 415.     CrossRef
• Cancer Cell Resistance to Aurora Kinase Inhibitors: Identification of Novel Targets for Cancer Therapy
  Rita Hrabakova, Madhu Kollareddy, Jirina Tyleckova, Petr Halada, Marian Hajduch, Suresh Jivan Gadher, Hana Kovarova
  Journal of Proteome Research.2013; 12(1): 455.     CrossRef
• Role of maspin in cancer
  Rossana Berardi, Francesca Morgese, Azzurra Onofri, Paola Mazzanti, Mirco Pistelli, Zelmira Ballatore, Agnese Savini, Mariagrazia De Lisa, Miriam Caramanti, Silvia Rinaldi, Silvia Pagliaretta, Matteo Santoni, Chiara Pierantoni, Stefano Cascinu
  Clinical and Translational Medicine.2013;[Epub]     CrossRef
• Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry
  Shiwu Wu, Lan Yu, Zenong Cheng, Wenqing Song, Lei Zhou, Yisheng Tao
  Journal of Huazhong University of Science and Technology [Medical Sciences].2012; 32(3): 346.     CrossRef
• Maspin: molecular mechanisms and therapeutic implications
  Thomas M. Bodenstine, Richard E. B. Seftor, Zhila Khalkhali-Ellis, Elisabeth A. Seftor, Philip A. Pemberton, Mary J. C. Hendrix
  Cancer and Metastasis Reviews.2012; 31(3-4): 529.     CrossRef
• Ganoderma tsugaeInduces S Phase Arrest and Apoptosis in Doxorubicin-Resistant Lung Adenocarcinoma H23/0.3 Cells via Modulation of the PI3K/Akt Signaling Pathway
  Yang-Hao Yu, Han-Peng Kuo, Hui-Hsia Hsieh, Jhy-Wei Li, Wu-Huei Hsu, Shih-Jung Chen, Muh-Hwan Su, Shwu-Huey Liu, Yung-Chi Cheng, Chih-Yi Chen, Ming-Ching Kao
  Evidence-Based Complementary and Alternative Medicine.2012; 2012: 1.     CrossRef
• Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer
  Yong-Jae Kwon, Seog Joo Lee, Jae Soo Koh, Sung Han Kim, Hae Won Lee, Moon Chul Kang, Jae Bum Bae, Young-Joon Kim, Jong Ho Park
  Journal of Thoracic Oncology.2012; 7(1): 20.     CrossRef
• Caffeic Acid Phenethyl Ester Suppresses the Proliferation of Human Prostate Cancer Cells through Inhibition of p70S6K and Akt Signaling Networks
  Chih-Pin Chuu, Hui-Ping Lin, Mark F. Ciaccio, John M. Kokontis, Ronald J. Hause, Richard A. Hiipakka, Shutsung Liao, Richard Baker Jones
  Cancer Prevention Research.2012; 5(5): 788.     CrossRef
• Maspin expression is regulated by the non-canonical NF-κB subunit in androgen-insensitive prostate cancer cell lines
  Feng Guo, Suya Kang, Peng Zhou, Linchuan Guo, Liang Ma, Jianquan Hou
  Molecular Immunology.2011; 49(1-2): 8.     CrossRef
• Omega-3-Polyunsaturated Fatty Acids Suppress Pancreatic Cancer Cell Growth in vitro and in vivo via Downregulation of Wnt/Beta-Catenin Signaling
  Kyoung-Sub Song, Kaipeng Jing, Jong-Seok Kim, Eun-Jin Yun, Soyeon Shin, Kang-Sik Seo, Ji-Hoon Park, Jun-Young Heo, Jing X. Kang, Kwang-Sun Suh, Tong Wu, Jong-Il Park, Gi-Ryang Kweon, Wan-Hee Yoon, Byung-Doo Hwang, Kyu Lim
  Pancreatology.2011; 11(6): 574.     CrossRef
• Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells
  Kyoung-Sub Song, Ge Li, Jong-Seok Kim, Kaipeng Jing, Tae-Dong Kim, Jin-Pyo Kim, Seung-Bo Seo, Jae-Kuk Yoo, Hae-Duck Park, Byung-Doo Hwang, Kyu Lim, Wan-Hee Yoon
  BMC Cancer.2011;[Epub]     CrossRef
• Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53
  Kaipeng Jing, Kyoung-Sub Song, Soyeon Shin, Nayeong Kim, Soyeon Jeong, Hye-Rim Oh, Ji-Hoon Park, Kang-Sik Seo, Jun-Young Heo, Jeongsu Han, Jong-Il Park, Chang Han, Tong Wu, Gi-Ryang Kweon, Seung-Kiel Park, Wan-Hee Yoon, Byung-Doo Hwang, Kyu Lim
  Autophagy.2011; 7(11): 1348.     CrossRef
• Reactivation ofMASPINin non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs)
  Adriana S. Beltran, Pilar Blancafort
  Epigenetics.2011; 6(2): 224.     CrossRef
• Suppression of Breast Tumor Growth and Metastasis by an Engineered Transcription Factor
  Adriana S. Beltran, Angela Russo, Haydee Lara, Cheng Fan, Paul M. Lizardi, Pilar Blancafort, Austin John Cooney
  PLoS ONE.2011; 6(9): e24595.     CrossRef

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Epidemiological studies have demonstrated an increased risk of subsequent cancer in the patients who are diagnosed with idiopathic venous thrombosis. Cancers of the breast, lung and ovary in women and adenocarcinomas of an unknown primary cancer are most strongly associated with thrombosis. Mucin-producing cancers are most often associated with VTE and the highest rates of VTE were found for cases of ovarian cancer, but the absolute risk of cancer after thrombosis is relatively low (about 2% over the first year) and so the benefit of screening for cancer in thrombosis patients seems limited. But as this case, the association between thrombosis and occult cancer shows the importance of this association for patients who have thrombosis that is unresponsive to anticoagulant therapy. Especially, we should recognize that such patients can undergo investigation for an underlying malignancy. Diagnostic laparoscopy of an adnexal mass for confirming cancer in the acute setting of deep vein thrombosis (DVT) was performed for our patient. We report here on a case of a patient with DVT in the upper and lower extremities before the diagnosis of ovarian cancer, and we briefly review of the relevant literature.

Citations

Citations to this article as recorded by  

• Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy
  Qinhui Dong, Xiayin Zhu, Yafen Gao, Zhengrong Wang, Dexing Zheng, Jian Zhu, Pan Zheng
  Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
• Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient
  Masahito Naito, Ryota Torii, Yuki Hashimoto, Yuki Kawamoto, Kenichi Hayashi, Hiroaki Shinoda, Yumiko Honjo, Motoki Hiroyoshi
  Chemotherapy.2019; 64(3): 163.     CrossRef
• Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review
  HONGWEI SHEN, JIANHONG SHANG, GANG NIU, JUN LIU, ZESHAN YOU, SHANYANG HE
  Oncology Letters.2015; 10(4): 2579.     CrossRef

Multiple primary cancers are the occurrence of more than two cancers of different origin in an individual. Penile cancer is a rare disease, and finding it combined with other cancers is even rarer. A 64-year-old man with a painful penile mass was referred to us from a primary urological clinic. We performed a biopsy of the penile mass and the histology revealed a well-differentiated squamous cell carcinoma. Abdominal computed tomography showed a localized bladder tumor with inguinal lymphadenopathy. The patient underwent a partial penectomy, transurethral resection of the bladder tumor and inguinal lymph node dissection. The histology of the bladder tumor was high-grade papillary carcinoma, and that of the lymph node was squamous cell carcinoma. The penile and bladder tumors were in stage II (T1N1M0) and stage I (T1N0M0), respectively. We successfully treated the patient with adjuvant radiotherapy and systemic chemotherapy.

Citations

Citations to this article as recorded by  

• Synchronous Double Primary Cancer of the Penisand Urinary Bladder
  Deora H
  MOJ Surgery.2017;[Epub]     CrossRef

A dedifferentiated liposarcoma of the retroperitoneum is an extremely rare tumor. A 51-year old man was admitted to our department because a retroperitoneal mass was seen on abdominal computed tomography at another hospital. Computed tomography of the abdomen and magnetic resonance imaging showed a large pelvic mass located in the right hemipelvis, and it was pushing the right ureter and invading the right kidney, duodenum, colon and inferior vena cava. The patient underwent right radical nephrectomy, pylorus preserving pancreatoduodenectomy, right hemicolectomy and artificial blood vessel replacement for the inferior vena cava. The histopathological diagnosis was dedifferentiated liposarcoma and the patient was free from recurrence on the computed tomography that was done 6 months after the operation.

Citations

Citations to this article as recorded by  

• Characterizing the Transformation and Diagnosis of Atypical Lipomatous Tumor to Dedifferentiated Liposarcoma: Single Institutional Outcomes
  Zachary Butler, Austin Yu, Lesly Honore, Anne Timmermann, Matthew Demetrious, Steven Gitelis, Ira Miller, Alan Blank
  Journal of Surgical Oncology.2025; 131(3): 507.     CrossRef
• Giant retroperitoneal liposarcoma with colonic infiltration as a cause of gastrointestinal bleeding: Case report and literature review
  Sebastian Forero-Escobedo, Sandra Milena Gonzalez-Rodriguez, Jose Alejandro Ramírez-Rincón, Vanessa Alejandra Garcia-Bernal, Santiago Polanco-Perdomo, Sofía Echeverri-Torrents
  International Journal of Surgery Case Reports.2025; 129: 111142.     CrossRef
• Analysis of potential risk factors in the survival of patients with primary retroperitoneal liposarcoma
  Alessandro Bianchi, Alberto Pagan-Pomar, Rafael Ramos-Asensio, Pablo Luna-Fra, Marina Jiménez-Segovia, Natalia Pujol-Cano, Aina Ochogavia-Seguí, José Antonio Martínez-Corcoles, Francesc Xavier González-Argenté
  Cirugía Española.2022; 100(11): 691.     CrossRef
• Analysis of potential risk factors in the survival of patients with primary retroperitoneal liposarcoma
  Alessandro Bianchi, Alberto Pagan-Pomar, Rafael Ramos-Asensio, Pablo Luna-Fra, Marina Jiménez-Segovia, Natalia Pujol-Cano, Aina Ochogavia-Seguí, José Antonio Martínez-Corcoles, Francesc Xavier González-Argenté
  Cirugía Española (English Edition).2022; 100(11): 691.     CrossRef
• Challenging retrovesical mass in men: report of a rare liposarcoma case with concurrent COVID-19 infection
  Indah Jamtani, Adianto Nugroho, Nur Rahadiani, R Semuel W Manangka
  BMJ Case Reports.2021; 14(3): e241466.     CrossRef
• Recurrent retroperitoneal liposarcoma: A case report and literature review
  Francesk Mulita, Georgios‐Ioannis Verras, Elias Liolis, Levan Tchabashvili, Dimitrios Kehagias, Charalampos Kaplanis, Ioannis Perdikaris, Ioannis Kehagias
  Clinical Case Reports.2021;[Epub]     CrossRef
• Retroperitoneal liposarcoma in older person – a rare case report
  Navas Nadukkandiyil, Sameer Valappil, Marwan Ramadan, Essa Al Sulaiti, Hanadi Khamis Alhamad
  The Aging Male.2020; 23(5): 1509.     CrossRef
• Giant Retroperitoneal Dedifferentiated Liposarcoma: A Case Report
  Dobromir D. Dimitrov
  Journal of Biomedical and Clinical Research.2020; 13(1): 67.     CrossRef
• Dedifferentiated retroperitoneal liposarcoma spontaneously occurring in an aged SD rat
  Tomoharu Naito, Tsuyoshi Saito, Tamami Higuchi, Akira Inomata, Takuo Hayashi, Yasuhiro Shimada, Atsuko Yamauchi-Ohguchi, Sayaka Kenmochi, Chihaya Kakinuma, Takashi Yao
  Journal of Toxicologic Pathology.2018; 31(2): 141.     CrossRef
• An unusual case of recurrent huge primary mediastinal dedifferentiated liposarcoma
  Noni Novisari Soeroso, Andika Pradana, Marshal Djaka, Maulidya Ayudika, Soekimin Ngadimin, Luhur Soeroso
  International Journal of Surgery Case Reports.2018; 50: 140.     CrossRef
• Giant primary liposarcoma of the anterior mediastinum
  Yu-Shang Yang, Cheng-Yun Bai, Zhong-Cheng Li, Wen-Jun Li, Yong Li
  Medicine.2018; 97(42): e12873.     CrossRef
• Soft-Tissue Sarcomas of the Abdomen and Pelvis: Radiologic-Pathologic Features, Part 1—Common Sarcomas:From the Radiologic Pathology Archives
  Angela D. Levy, Maria A. Manning, Waddah B. Al-Refaie, Markku M. Miettinen
  RadioGraphics.2017; 37(2): 462.     CrossRef
• Giant dedifferentiated liposarcoma of small bowel mesentery: a case report
  Susanta Meher, Tushar Subhadarshan Mishra, Satyajit Rath, Prakash Kumar Sasmal, Pritinanda Mishra, Susama Patra
  World Journal of Surgical Oncology.2016;[Epub]     CrossRef
• Exophytic renal angiomyolipoma and perirenal liposarcoma: revisiting the role of CT for differential diagnosis
  Sungmin Woo, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim, Myoung Seok Lee
  Acta Radiologica.2016; 57(2): 249.     CrossRef
• Mesenchymal tumors of adult kidney
  Hemamali Samaratunga, Brett Delahunt
  Seminars in Diagnostic Pathology.2015; 32(2): 160.     CrossRef
• Prognostic Factors Predicting the Postoperative Survival Period Following Treatment for Primary Retroperitoneal Liposarcoma
  Xudong Zhao, Peiyu Li, Xiaohui Huang, Lin Chen, Na Liu, Yaoguang She
  Chinese Medical Journal.2015; 128(1): 85.     CrossRef
• Retroperitoneal Liposarcoma with Colonic Involvement: A Case Report
  Y. Sato, S. Yamamoto, S. Fujita
  Japanese Journal of Clinical Oncology.2014; 44(4): 374.     CrossRef
• Dedifferentiated Liposarcoma Arising from the Mesocolon Ascendens: Report of a Case
  Kohki Takeda, Takayuki Aimoto, Masato Yoshioka, Yoshiharu Nakamura, Kazuya Yamahatsu, Toshiyuki Ishiwata, Zenya Naito, Masao Miyashita, Eiji Uchida
  Journal of Nippon Medical School.2012; 79(5): 385.     CrossRef
• A huge retroperitoneal liposarcoma presenting as a hepatic space‐occupying lesion: A case report
  Jing Fei TENG, Xin ZENG, Jian SHI, Wei Fen XIE, Yong LIN
  Journal of Digestive Diseases.2012; 13(2): 120.     CrossRef
• A case of perinephric liposarcoma which recurred ten years later from the initial operation
  Shinji Kuratate, Motoya Chikakiyo, Yuji Kaneda, Yukari Harino, Toshiyuki Hirose, Toshiyuki Yagi, Seiya Saitoh, Masayuki Sumitomo, Ryozo Fujino, Nobuo Satake, Takahiro Hirose
  The Journal of Medical Investigation.2011; 58(1,2): 154.     CrossRef